440 related articles for article (PubMed ID: 29562511)
1. Clinical Trials for Disease-Modifying Therapies in Alzheimer's Disease: A Primer, Lessons Learned, and a Blueprint for the Future.
Cummings J; Ritter A; Zhong K
J Alzheimers Dis; 2018; 64(s1):S3-S22. PubMed ID: 29562511
[TBL] [Abstract][Full Text] [Related]
2. Biomarker and Clinical Trial Design Support for Disease-Modifying Therapies: Report of a Survey of the EU/US: Alzheimer's Disease Task Force.
Cummings J; Fox N; Vellas B; Aisen P; Shan G
J Prev Alzheimers Dis; 2018; 5(2):103-109. PubMed ID: 29616703
[TBL] [Abstract][Full Text] [Related]
3. Defining Disease Modifying Therapy for Alzheimer's Disease.
Cummings J; Fox N
J Prev Alzheimers Dis; 2017; 4(2):109-115. PubMed ID: 29071250
[TBL] [Abstract][Full Text] [Related]
4. Alzheimer's disease drug development pipeline: 2017.
Cummings J; Lee G; Mortsdorf T; Ritter A; Zhong K
Alzheimers Dement (N Y); 2017 Sep; 3(3):367-384. PubMed ID: 29067343
[TBL] [Abstract][Full Text] [Related]
5. Drug Development for Psychotropic, Cognitive-Enhancing, and Disease-Modifying Treatments for Alzheimer's Disease.
Cummings J
J Neuropsychiatry Clin Neurosci; 2021; 33(1):3-13. PubMed ID: 33108950
[TBL] [Abstract][Full Text] [Related]
6. Using cognitive decline in novel trial designs for primary prevention and early disease-modifying therapy trials of Alzheimer's disease.
Darby D; Brodtmann A; Woodward M; Budge M; Maruff P
Int Psychogeriatr; 2011 Nov; 23(9):1376-85. PubMed ID: 21477408
[TBL] [Abstract][Full Text] [Related]
7. Biomarkers in Alzheimer's disease drug development.
Cummings JL
Alzheimers Dement; 2011 May; 7(3):e13-44. PubMed ID: 21550318
[TBL] [Abstract][Full Text] [Related]
8. Defining and labeling disease-modifying treatments for Alzheimer's disease.
Cummings JL
Alzheimers Dement; 2009 Sep; 5(5):406-18. PubMed ID: 19751920
[TBL] [Abstract][Full Text] [Related]
9. The "rights" of precision drug development for Alzheimer's disease.
Cummings J; Feldman HH; Scheltens P
Alzheimers Res Ther; 2019 Aug; 11(1):76. PubMed ID: 31470905
[TBL] [Abstract][Full Text] [Related]
10. Designing drug trials for Alzheimer's disease: what we have learned from the release of the phase III antibody trials: a report from the EU/US/CTAD Task Force.
Vellas B; Carrillo MC; Sampaio C; Brashear HR; Siemers E; Hampel H; Schneider LS; Weiner M; Doody R; Khachaturian Z; Cedarbaum J; Grundman M; Broich K; Giacobini E; Dubois B; Sperling R; Wilcock GK; Fox N; Scheltens P; Touchon J; Hendrix S; Andrieu S; Aisen P;
Alzheimers Dement; 2013 Jul; 9(4):438-44. PubMed ID: 23809364
[TBL] [Abstract][Full Text] [Related]
11. Drug development in Alzheimer's disease: the path to 2025.
Cummings J; Aisen PS; DuBois B; Frölich L; Jack CR; Jones RW; Morris JC; Raskin J; Dowsett SA; Scheltens P
Alzheimers Res Ther; 2016 Sep; 8():39. PubMed ID: 27646601
[TBL] [Abstract][Full Text] [Related]
12. [Current Clinical Trials in the Treatment of Alzheimer's Disease].
Tamaoka A
Brain Nerve; 2020 Jan; 72(1):23-34. PubMed ID: 31907330
[TBL] [Abstract][Full Text] [Related]
13. Prevention Trials in Alzheimer's Disease: Current Status and Future Perspectives.
Wang J; Tan L; Yu JT
J Alzheimers Dis; 2016; 50(4):927-45. PubMed ID: 26836177
[TBL] [Abstract][Full Text] [Related]
14. Cerebrospinal Fluid Biomarkers for Target Engagement and Efficacy in Clinical Trials for Alzheimer's and Parkinson's Diseases.
Parnetti L; Eusebi P; Lleó A
Front Neurol Neurosci; 2016; 39():117-23. PubMed ID: 27463974
[TBL] [Abstract][Full Text] [Related]
15. What works and what does not work in Alzheimer's disease? From interventions on risk factors to anti-amyloid trials.
Bullain S; Doody R
J Neurochem; 2020 Sep; 155(2):120-136. PubMed ID: 32277473
[TBL] [Abstract][Full Text] [Related]
16. A new proposal for randomized start design to investigate disease-modifying therapies for Alzheimer disease.
Zhang RY; Leon AC; Chuang-Stein C; Romano SJ
Clin Trials; 2011 Feb; 8(1):5-14. PubMed ID: 21335586
[TBL] [Abstract][Full Text] [Related]
17. Alzheimer's drug-development pipeline: 2016.
Cummings J; Morstorf T; Lee G
Alzheimers Dement (N Y); 2016 Nov; 2(4):222-232. PubMed ID: 29067309
[TBL] [Abstract][Full Text] [Related]
18. Prevention of sporadic Alzheimer's disease: lessons learned from clinical trials and future directions.
Andrieu S; Coley N; Lovestone S; Aisen PS; Vellas B
Lancet Neurol; 2015 Sep; 14(9):926-944. PubMed ID: 26213339
[TBL] [Abstract][Full Text] [Related]
19. Disease modification and Neuroprotection in neurodegenerative disorders.
Cummings J
Transl Neurodegener; 2017; 6():25. PubMed ID: 29021896
[TBL] [Abstract][Full Text] [Related]
20. The use of cerebrospinal fluid biomarkers to measure change in neurodegeneration in Alzheimer's disease clinical trials.
Olsson B; Schott JM; Blennow K; Zetterberg H
Expert Rev Neurother; 2017 Aug; 17(8):767-775. PubMed ID: 28604243
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
